Company Filing History:
2 out of 4 
1 out of 1,580 
Years Active: 2022-2024
Title: Jung Hak Lim: Innovator in Cancer Treatment
Introduction
Jung Hak Lim is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer treatment through his innovative pharmaceutical compositions. With a total of 2 patents, his work focuses on utilizing advanced technologies to enhance the specificity and effectiveness of cancer therapies.
Latest Patents
One of his latest patents is a pharmaceutical composition for treating cancer, which contains guide RNA and endonuclease as active ingredients. This composition can be customized according to the needs of patients or specific cell types, allowing for targeted treatment of cancer cells based on the unique binding properties of DNA and RNA. The CRISPR PLUS system, which includes both an endonuclease and an exonuclease, can be activated through the binding of crRNA to genes specifically found in cancer cells. This results in a more precise cancer treatment effect compared to other anti-cancer agents currently available.
Another notable patent involves enhanced, specific nucleic acid targeting complexes that comprise endo and exonuclease activity. This innovation allows for the targeted degradation of specific and non-specific nucleic acids in vivo, as well as the temporal regulation of nuclease activity to prevent off-target effects. Through this method, nucleic acids and cells harboring them, such as cancer cells or pathogens, can be selectively degraded in vivo.
Career Highlights
Jung Hak Lim has worked with notable organizations, including Gflas Life Sciences, Inc. and Seoul National University. His experience in these institutions has contributed to his expertise in developing cutting-edge cancer treatment solutions.
Collaborations
He has collaborated with talented individuals such as Sunghwa Choe and Mi Jin Park, further enhancing the impact of his work in the field of cancer research.
Conclusion
Jung Hak Lim's innovative contributions to cancer treatment through his patented technologies demonstrate his commitment to advancing medical science. His work not only showcases his expertise but also holds the potential to significantly improve patient outcomes in cancer therapy.